GLORIA-AF Registry Program (Phase I)

• CHADS2 Score [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  CHADS2 score is based on a point system in which 2 points are assigned for a history of stroke or transient ischemic attack and 1 point each is assigned for age equal to or greater more than 75 years, hypertension, diabetes, or clinical heart failure or impaired left ventricular systolic function (generally interpreted as an ejection fraction ≤ 40%).
• CHA2DS2-VASc Score [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  The CHA2DS2-VASc risk score is based on a point system in which 2 points are assigned for a history of stroke or TIA, or age ≥75; and 1 point each is assigned for age 65-74 years, a hypertension, diabetes, cardiac failure, vascular disease and female sex. On the basis of the risk strata defined in previous guidelines, a CHA2DS2-VASc score of 0 corresponds to "low risk", a score of 1 corresponds to "intermediate risk", and a score of 2 or more corresponds to "high risk".
• HAS-BLED Risk Score [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  The HAS-BLED score is based on a point system in which 1 point is assigned for hypertension (systolic blood pressure >160 mmHg), 1 point for each of abnormal renal (presence of chronic dialysis or renal transplantation or serum creatinine ≥200 μmol/L) and liver (chronic hepatic disease or biochemical evidence of significant hepatic derangement) function, 1 point each is assigned for stroke, bleeding (previous bleeding history and/or predisposition to bleeding), labile Internation Normalized Ratios (INRs,unstable/high INRs or poor time in therapeutic range), age >65 years and 1 point each for drugs (such as antiplatelet agents, non-steroidal anti-inflammatory drugs) or alcohol.
• Antithrombotic Treatment Choice at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
• Gender [ Time Frame: Baseline ] [ Designated as safety issue: No ]
• Age Group [ Time Frame: Baseline ] [ Designated as safety issue: No ]
• Medical History [ Time Frame: Baseline ] [ Designated as safety issue: No ]
• Concomitant Medication [ Time Frame: Baseline ] [ Designated as safety issue: No ]

• CHADS2 Score [cardiac failure, hypertension, age, diabetes, stroke (doubled)] [ Time Frame: 1 day ] [ Designated as safety issue: No ]
• CHA2DS2-VASc Score [cardiac failure, hypertension, age >= 75 (doubled), diabetes,stroke (doubled), vascular disease, age 65-74 and sex category (female)] [ Time Frame: 1 day ] [ Designated as safety issue: No ]
• HAS-BLED Score [hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile International Normalized Ratio (INR), elderly (>65), drugs/alcohol concomitantly (1 point each)] [ Time Frame: 1 day ] [ Designated as safety issue: No ]
• Antithrombotic Treatment Choice at Baseline [ Time Frame: 1 day ] [ Designated as safety issue: No ]
• Gender [ Time Frame: 1 day ] [ Designated as safety issue: No ]
• Age Group [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Study Design:

cross-sectional

Inclusion criteria:

1) Patients newly diagnosed with non-valvular atrial fibrillation at risk for stroke.

Exclusion criteria:

1. Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention;
2. Patients who have received more than 60 days of oral anticoagulant treatment (vitamin K antagonist) (VKA) in their lifetime;
3. Atrial fibrillation (AF) with a generally reversible cause;
4. Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (VKAs) is indicated